Product: Dupixent

October 19, 2024, 13:30 – 14:30

Session Description:

Emerging Perspectives on Disease Burden and Management of Children with Atopic Dermatitis – Industry Symposium Sponsored by Sanofi Atopic dermatitis (AD) is a chronic inflammatory disease with cutaneous and systemic effects that can lead to significant disease burden in children and their caregivers. This symposium will discuss diagnosis of AD in children, the inflammatory processes driven by type 2 cytokines that lead to AD and atopic comorbidities, and emerging treatment options in the management of AD in children who are candidates for systemic therapy. The overall burden of uncontrolled AD in children can lead to cumulative, life-long effects that can alter the life course of the patient, suggesting an urgency to treat AD in children.

Note that this recording is intended for HCPs only.

Session programme:

• WELCOME, OBJECTIVES, AND AUDIENCE POLLING – Perla Lansang (Canada)
• TYPE 2 INFLAMMATION AND ITS ROLE IN AD – Christine Bangert (Austria)
•   AD IN CHILDREN – NOT JUST A SKIN DISEASE – Mark Boguniewicz (United States of America)
• CURRENT AND EMERGING THERAPEUTIC OPTIONS FOR CHILDREN WITH AD – Perla Lansang (Canada)
• CONCLUSIONS AND Q&A

October 19, 2024, 13:30 – 14:30

Session Description:

Optimizing management of the febrile child – Can we reduce invasive procedures, antibiotic prescriptions and hospitalizations using biomarkers? Fever without source represents a diagnostic challenge in infants and children. While existing models, rules, guidelines, and experienced clinicians demonstrate high sensitivity, their specificity is often low to modest, leading to increased invasiveness, hospitalizations, antimicrobial usage, and costs. Incorporating PCT, in conjunction with other variables, has been shown to significantly enhance specificity, thereby mitigating iatrogenic medical and social consequences. It is especially useful in infants coming to care within a few hours of fever onset.

• Learn about the diagnostic accuracy of PCT for invasive bacterial infections and its superior specificity.
• Learn about a cluster-randomized trial (4920 patients aged 6 hours to 36 months) in France for a decision-making algorithm for management of fever without source that includes PCT and its effect on antibiotic prescriptions.
• Learn what the guidelines recommend on PCT usage, how it can be implemented and the impact it can have on clinical practice as studied in Quality Improvement Initiatives

Robert H. Pantell

Alain Gervaix

Christèle Gras-Le Guen

Note that this recording is intended for HCPs only.

Session programme:

• INTRODUCTIONS  – Robert H. Pantell (United States of America)
•  CHALLENGES IN THE EARLY DIAGNOSIS OF SEVERE AND INVASIVE BACTERIAL INFECTIONS – Alain Gervaix (Switzerland)
•  REDUCING ANTIBIOTIC PRESCRIPTIONS IN PATIENTS WITH FEVER WITHOUT SOURCE: RESULTS FROM THE DIAFEVER CHILD CLUSTER RANDOMIZED TRIAL – Christèle Gras-Le Guen (France)
•   MANAGING FEVER WITHOUT SOURCE: WHAT DO THE GUIDELINES SAY? – Robert H. Pantell (United States of America)
• Q&A